Fig. 3From: Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorderReturn to Baseline Weight After Treatment Interruption With Oral SGAs Associated With Moderate to High Risk of Weight Gain. BD-I, bipolar I disorder; CSWG, clinically significant weight gain; SGA, second-generation antipsychotic; SZ, schizophreniaBack to article page